MRD-directed and risk-adapted individualized stratified treatment of AML

Measurable residual disease (MRD) has been widely recognized as a biomarker for deeply evaluating complete remission (CR), predicting relapse, guiding pre-emptive interventions, and serving as an endpoint surrogate for drug testing. However, despite the emergence of new technologies, there remains a...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Chinese journal of cancer research 2023-10, Vol.35 (5), p.451-469
Hauptverfasser:	Zhao, Yijing, Guo, Hanfei, Chang, Yingjun
Format:	Artikel
Sprache:	eng
Schlagworte:	Review
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!